PURE GLOBAL POISED TO ADVANCE ITS INNOVATIVE PRODUCTS TO DISTRIBUTION CHANNELS

Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) is a growth-oriented life sciences cannabis company which plans to serve the market based on its research driven medical cannabis strategy. Pure recently announced that it is launching eight product lines for medical cannabis patients under the company’s PureSinse packaging label.

Innovative Medical Cannabis and Health & Wellness Products

The new PureSinse product line includes eight stock keeping units (SKUs) featuring a wide spectrum of products, formulations and infusions for the medical and health & wellness markets. The elegant, eco-friendly, and sustainable packaging speaks to the PureSinse culture of providing its clientele with exceptional product offerings and customer experience across all aspects of their company. An assortment of dried flower, cannabis oils, softgels, topicals, sublinguals, transdermals, edibles, and vape products are in the final stages of development to make them readily available to meet each patient’s individual needs once the company’s Health Canada sales license is in hand, which could happen in the next few weeks.

In further developments, the company is expecting to unveil a user-friendly eCommerce website that will enable medical cannabis patients to register with PureSinse, order medical cannabis online, and enjoy discreet delivery via registered courier in selected areas.

Health Canada Sales License

PureSinse recently completed the physical on-site inspections required by Health Canada prior to being granted a sales license to supply cannabis products to medical patients, as well legal adult markets, under the newly implemented Cannabis Act 2018. “We are confident that we have met all the safety, quality assurance, security, and record keeping requirements,” said Malay Panchal, CEO of Pure Global. “The inspection by Health Canada was one of the last steps prior to issuing a sales license, which will be a significant milestone for the company enabling sale of cannabis inventories to registered medical patients and provincial distributors, and the initiation of revenues for the company.”

About PureSinse

PureSinse, a wholly owned subsidiary of Pure Global, Inc, has demonstrated a commitment to a clinical approach that stems from the company’s pharmacy and physician roots. “The PureSinse brand is focused on patients,” according to Cheryl Pim, Director of New Product Development. “We will be tracking clinical outcomes through real-world studies to ensure our product lines are consistent, tailored, and available. Patients rely on consistency and dependability for their medical needs, and our research and data-driven approach will ensure our products and methods improve and evolve with the needs of our patients over time.”

Pure Global’s Brampton Operation

Pure’s commitment to continuous improvement and innovation is further evident in Pure Global’s recent acquisition of CO2 extraction, high-capacity robotic capsules, oil bottles, and vape pen cartridge filling equipment. The company’s Brampton campus has quickly transformed into a hub for a vertically farmed cultivation, high capacity extraction, laboratory testing, research and development, and a manufacturing center for branded and private label products for the wellness, food & beverage, natural health, and pharmaceutical markets.

In Brampton Phase 2 & Phase 3 construction of Pure’s 41,000 square foot production facility will include automated controlled growth cultivation systems that feature the company’s vertical farming methods.   This proprietary vertical farming system enables the facility to grow multiple tiers of canopy, exponentially increasing potential yield from the same square footage, without the use of pesticides or herbicides. Upon  expected completion in Q3 or Q4 of 2019, Pure’s Brampton production facility is anticipated to have a production capacity of minimum 8,000 kilograms.

Patient Focused Solutions for Improved Patient Outcomes

To support Pure’s continued focus on innovations in medical cannabis with the aim of helping patients across the globe, the company recently welcomed Dr. Sanjeev Goel to the PureSinse team as Chief Medical Officer. Dr. Goel, with a wealth of experience in the industry, has been a pioneer in medical cannabis. He led the formation of two resource centers for medical cannabis with over 3000 patients registered with licensed producers in Canada. Dr Goel is founder and CEO for an integrative medical practice using cutting-edge medical treatments for patients across Canada, the founder of a not-for-profit organization dedicated to empowering health care providers to improve patient care, as well as a healthcare software company to improve patient quality of care by developing the largest primary care patient portal in Canada.

Dr Goel will provide direction on projects supporting medical cannabis patients, primarily having to do with patient care experience and physician education. He will also act as the lead liaison with doctors and medical professionals, to provide guidance on medical cannabis and systems to ensure efficient, accurate patient care.

“I am thrilled to add Dr. Goel to our core team to help deliver patient-focused solutions enabling better education and ultimately improved patient outcomes”, said Malay Panchal. “Dr. Goel’s extensive experience as a practicing physician will allow him to offer advice regarding clinical research projects, strategies to address the needs of wellness customers, and ways to integrate existing and new wellness products.”

With these recent positive developments, Pure Global Inc appears to be a company to watch as a potential leader in the cannabis industry in Canada and worldwide.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.